FDA To Consider Regulatory Shift Making Cannabis Ingredients Officially Eligible For Use In Dietary Supplements
FDA's prohibition against using ingredients derived from the cannabis plant in supplements and food isn't lifted by the farm bill President Trump signed on Dec. 20, but the agency recognizes sales of supplement and food products containing cannabidiol and other cannabis derivatives are exploding in the US.
You may also be interested in...
“Irrational exuberance was an understatement for what people thought of the CBD market in 2018 and 2019,” says an attorney specializing in hemp regulations. In 2019, CBD isolate could be sold for “upwards of $12,000 a kilogram,” but price now is less than $1,000.
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.
New York proposal for packaging and testing hemp-derived cannabinoids could be ‘de facto’ standard for other stat, say attorneys tracking the patchwork of state laws. The proposal sets per-product concentration limits and includes licensing fees for processors and retailers.